232 related articles for article (PubMed ID: 26621838)
1. The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction.
Oudart JB; Doué M; Vautrin A; Brassart B; Sellier C; Dupont-Deshorgue A; Monboisse JC; Maquart FX; Brassart-Pasco S; Ramont L
Oncotarget; 2016 Jan; 7(2):1516-28. PubMed ID: 26621838
[TBL] [Abstract][Full Text] [Related]
2. Type XIX collagen: A new partner in the interactions between tumor cells and their microenvironment.
Oudart JB; Monboisse JC; Maquart FX; Brassart B; Brassart-Pasco S; Ramont L
Matrix Biol; 2017 Jan; 57-58():169-177. PubMed ID: 27491275
[TBL] [Abstract][Full Text] [Related]
3. Conformation-dependent binding of a Tetrastatin peptide to α
Lambert E; Fuselier E; Ramont L; Brassart B; Dukic S; Oudart JB; Dupont-Deshorgue A; Sellier C; Machado C; Dauchez M; Monboisse JC; Maquart FX; Baud S; Brassart-Pasco S
Sci Rep; 2018 Jun; 8(1):9837. PubMed ID: 29959360
[TBL] [Abstract][Full Text] [Related]
4. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
[TBL] [Abstract][Full Text] [Related]
5. The NC1 domain of type XIX collagen inhibits melanoma cell migration.
Toubal A; Ramont L; Terryn C; Brassart-Pasco S; Patigny D; Sapi J; Monboisse JC; Maquart FX
Eur J Dermatol; 2010; 20(6):712-8. PubMed ID: 20840910
[TBL] [Abstract][Full Text] [Related]
6. The NC1 domain of type XIX collagen inhibits in vivo melanoma growth.
Ramont L; Brassart-Pasco S; Thevenard J; Deshorgue A; Venteo L; Laronze JY; Pluot M; Monboisse JC; Maquart FX
Mol Cancer Ther; 2007 Feb; 6(2):506-14. PubMed ID: 17308049
[TBL] [Abstract][Full Text] [Related]
7. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways.
Yang L; Hou Y; Yuan J; Tang S; Zhang H; Zhu Q; Du YE; Zhou M; Wen S; Xu L; Tang X; Cui X; Liu M
Oncotarget; 2015 Sep; 6(28):25755-69. PubMed ID: 26342198
[TBL] [Abstract][Full Text] [Related]
8. PDK1 is a potential therapeutic target against angiosarcoma cells.
Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
[TBL] [Abstract][Full Text] [Related]
9. Disintegrin Tablysin-15 Suppresses Cancer Hallmarks in Melanoma Cells by Blocking FAK/Akt/ERK and NF-κB Signaling.
Deng Z; Zeng Q; Chai J; Zhang B; Zheng W; Xu X; Wu J
Curr Cancer Drug Targets; 2020; 20(4):306-315. PubMed ID: 31893992
[TBL] [Abstract][Full Text] [Related]
10. Vitronectin-αvβ3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells.
Pola C; Formenti SC; Schneider RJ
Cancer Res; 2013 Jul; 73(14):4571-8. PubMed ID: 23722547
[TBL] [Abstract][Full Text] [Related]
11. Plasmin releases the anti-tumor peptide from the NC1 domain of collagen XIX.
Oudart JB; Brassart-Pasco S; Vautrin A; Sellier C; Machado C; Dupont-Deshorgue A; Brassart B; Baud S; Dauchez M; Monboisse JC; Harakat D; Maquart FX; Ramont L
Oncotarget; 2015 Feb; 6(6):3656-68. PubMed ID: 25668817
[TBL] [Abstract][Full Text] [Related]
12. Periostin of human periodontal ligament fibroblasts promotes migration of human mesenchymal stem cell through the αvβ3 integrin/FAK/PI3K/Akt pathway.
Matsuzawa M; Arai C; Nomura Y; Murata T; Yamakoshi Y; Oida S; Hanada N; Nakamura Y
J Periodontal Res; 2015 Dec; 50(6):855-63. PubMed ID: 25900259
[TBL] [Abstract][Full Text] [Related]
13. F4, a collagen XIX-derived peptide, inhibits tumor angiogenesis through αvβ3 and α5β1 integrin interaction.
Oudart JB; Villemin M; Brassart B; Sellier C; Terryn C; Dupont-Deshorgue A; Monboisse JC; Maquart FX; Ramont L; Brassart-Pasco S
Cell Adh Migr; 2021 Dec; 15(1):215-223. PubMed ID: 34308743
[TBL] [Abstract][Full Text] [Related]
14. Melittin suppresses EGF-induced cell motility and invasion by inhibiting PI3K/Akt/mTOR signaling pathway in breast cancer cells.
Jeong YJ; Choi Y; Shin JM; Cho HJ; Kang JH; Park KK; Choe JY; Bae YS; Han SM; Kim CH; Chang HW; Chang YC
Food Chem Toxicol; 2014 Jun; 68():218-25. PubMed ID: 24675423
[TBL] [Abstract][Full Text] [Related]
15. Role of extracellular matrix renal tubulo-interstitial nephritis antigen (TINag) in cell survival utilizing integrin (alpha)vbeta3/focal adhesion kinase (FAK)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B-serine/threonine kinase (AKT) signaling pathway.
Xie P; Kondeti VK; Lin S; Haruna Y; Raparia K; Kanwar YS
J Biol Chem; 2011 Sep; 286(39):34131-46. PubMed ID: 21795690
[TBL] [Abstract][Full Text] [Related]
16. Effect of ligand conformation on melanoma cell alpha3beta1 integrin-mediated signal transduction events: implications for a collagen structural modulation mechanism of tumor cell invasion.
Lauer JL; Gendron CM; Fields GB
Biochemistry; 1998 Apr; 37(15):5279-87. PubMed ID: 9548759
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
18. Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways.
Wu MH; Lo JF; Kuo CH; Lin JA; Lin YM; Chen LM; Tsai FJ; Tsai CH; Huang CY; Tang CH
J Cell Physiol; 2012 Aug; 227(8):3016-26. PubMed ID: 21959927
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
20. CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin-dependent pathway.
Tzeng HE; Chen JC; Tsai CH; Kuo CC; Hsu HC; Hwang WL; Fong YC; Tang CH
J Cell Physiol; 2011 Dec; 226(12):3181-9. PubMed ID: 21344378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
